[3H]Tyramine uptake by rat liver slices.
Rat liver slices were employed as experimental model to characterise the system involved in the transport process which participates in liver tyramine uptake. The uptake of 0.4 micromol l-1of [3H]tyramine by rat liver slices was linear from 5 min up to the end of incubation. At 15 min the uptake was 4.58+/-0.18 pmol mg-1protein. The accumulation of [3H]tyramine was sensitive to temperature (69. 3+/-4.0% inhibition at 0 degrees C, P<0.001), to sodium omission replaced by 150 mmol l-1Tris or 110 mmol l-1Tris+40 mmol l-1choline (27.6+/-6.0%, P<0.01, and 24.6+/-3.8% inhibition, P<0.01, respectively), and the inhibition of Na+-K+-adenosine triphosphatase by 150 micromol l-1ouabain (20.4+/-2.6% decrease, P<0.01). Uptake of [3H]tyramine was cocaine- (10 micromol l-1) and desipramine- (1 micromol l-1) dependent (32.2+/-6.4%, P<0.05, and 31.6+/-4.0% inhibition, P<0.05, respectively). Uptake of [3H]tyramine in rat liver slices was not modified by 30 micromol l-1isoprenaline, 30 micromol l-1corticosterone, 30 micromol l-1normetanephrine and noradrenaline up to 4 micrometers at higher noradrenaline concentrations tyramine transport was diminished (P<0.05). Results achieved by incubation with increasing tyramine concentrations indicate that at the micromolar level hepatic uptake occurs by a combined passive diffusion and transport-mediated mechanism, whereas at greater tyramine concentrations passive transport predominates. These results suggest that both simple diffusion and a transport-mediated mechanism are involved in this uptake from hepatocytes, which presents features similar to those described for type 1 non-neuronal uptake systems.
Tchercansky
D M
DM
Cátedra de Farmacologiá, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, Buenos Aires, Argentina.
Rubio
M C
MC
Acevedo
C
C
D000305:Adrenal Cortex Hormones / Q000494:pharmacology; D018759:Adrenergic Uptake Inhibitors; D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D003042:Cocaine / Q000494:pharmacology; D003891:Desipramine / Q000494:pharmacology; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D008099:Liver / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009638:Norepinephrine / Q000493:pharmacokinetics; D009647:Normetanephrine / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012964:Sodium / Q000494:pharmacology; D013566:Sympathomimetics / Q000493:pharmacokinetics*; D013696:Temperature; D013997:Time Factors; D014316:Tritium; D014439:Tyramine / Q000493:pharmacokinetics*
D000305:Adrenal Cortex Hormones; D018759:Adrenergic Uptake Inhibitors; D018765:Dopamine Uptake Inhibitors; D013566:Sympathomimetics; D009647:Normetanephrine; D014316:Tritium; D012964:Sodium; D003042:Cocaine; D007545:Isoproterenol; D003891:Desipramine; D009638:Norepinephrine; D014439:Tyramine